In vivo antitumor efficacy of CLP nanoparticles after intravenous delivery
This protocol is extracted from research article:
A self-illuminating nanoparticle for inflammation imaging and cancer therapy
Sci Adv, Jan 9, 2019; DOI: 10.1126/sciadv.aat2953

Mice with subcutaneous A549 xenografts were randomly divided into three groups (n = 4). The control group was treated with saline by intravenous injection every 6 days, while the other two groups were separately administered with CLP nanoparticles at 5 or 25 mg/kg of Ce6. The tumor volume and body weight were monitored every 3 days. After 30 days, mice were euthanized. Tumor tissues and major organs were collected for further analyses.

In a separate study, in vivo antitumor efficacy and safety of CLP nanoparticles were compared with a typical chemotherapy drug, CDDP. A549 xenograft–bearing mice were randomly assigned into four groups (n = 5). The control group was treated with 0.1 ml of saline. The dose of CLP nanoparticles was equivalent to 25 mg/kg of Ce6. Mice in two CDDP groups were administered with CDDP at 1 or 6 mg/kg, which were labeled as CDDP-L and CDDP-H, respectively. All treatments were performed once every 3 days by intravenous injection. Tumor volume and body weight were measured every 3 days. After 14 days, mice were euthanized for additional analyses.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.